Key Points
- CFO Benjamin Hohl sold 6,018 Enliven Therapeutics shares at an average price of $58.58, generating $352,534.44. The sale was made under a pre-arranged Rule 10b5-1 plan and reduced his holdings by 13.07% to 40,036 shares.
- ELVN shares opened at $59.39, near their 52-week high of $62.32, with the stock’s 50-day and 200-day moving averages at $52.34 and $41.61, respectively. The company recently reported a quarterly loss of $0.49 per share, missing the consensus estimate of a $0.39 loss.
- Analyst sentiment remains broadly positive, with eight Buy ratings and one Sell rating producing a consensus “Moderate Buy” rating and an average price target of $75.00. Recent targets range as high as $80.00.
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction on Monday, August 17th. The shares were sold at an average price of $58.58, for a total value of $352,534.44. Following the completion of the transaction, the chief financial officer owned 40,036 shares of the company's stock, valued at approximately $2,345,308.88. This trade represents a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Benjamin Hohl also recently made the following trade(s):
- On Friday, July 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $52.64, for a total value of $316,787.52.
- On Wednesday, June 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $43.80, for a total value of $263,588.40.
Enliven Therapeutics Price Performance
Shares of NASDAQ ELVN opened at $59.39 on Thursday. The company has a market cap of $4.35 billion, a price-to-earnings ratio of -35.56 and a beta of 0.27. The stock's 50-day moving average is $52.34 and its two-hundred day moving average is $41.61. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $62.32.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). Equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.67 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on ELVN shares. JonesTrading increased their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a "buy" rating in a research report on Monday, June 29th. Mizuho lifted their price objective on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the stock an "outperform" rating in a research report on Tuesday. William Blair started coverage on shares of Enliven Therapeutics in a research note on Tuesday. They set an "outperform" rating for the company. Barclays began coverage on Enliven Therapeutics in a report on Tuesday. They issued an "overweight" rating and a $78.00 target price on the stock. Finally, The Goldman Sachs Group raised their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $75.00.
Check Out Our Latest Report on Enliven Therapeutics
Hedge Funds Weigh In On Enliven Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. KBC Group NV purchased a new position in Enliven Therapeutics in the first quarter valued at approximately $38,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock worth $44,000 after buying an additional 594 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after buying an additional 930 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Enliven Therapeutics in the 4th quarter valued at $83,000. Finally, Quantbot Technologies LP boosted its holdings in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock valued at $90,000 after buying an additional 1,434 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
